VECTURA GROUP |
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| Sales 2019 | 178M 224M 17.83B | Sales 2020 | 191M 239M 19.06B | Capitalization | 739M 927M 73.9B |
|---|---|---|---|---|---|
| Net income 2019 | -22M -27.61M -2.2B | Net income 2020 | 122M 153M 12.2B | EV / Sales 2019 | 2.8 x |
| Net cash position 2019 | 66.5M 83.44M 6.65B | Net cash position 2020 | 74.4M 93.36M 7.44B | EV / Sales 2020 | 3.49 x |
| P/E ratio 2019 |
-27.3
x | P/E ratio 2020 |
6.2
x | Employees | - |
| Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
| Chief Operating Officer | - | 30/06/17 | |
| Chief Tech/Sci/R&D Officer | - | 31/05/16 |
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Sector
-
- Stock Market
- Equities
- VEC Stock
- VEC Stock
